NASDAQ:SGMT Sagimet Biosciences Q4 2024 Earnings Report $7.16 -0.22 (-2.92%) As of 10:45 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sagimet Biosciences EPS ResultsActual EPS-$0.50Consensus EPS -$0.65Beat/MissBeat by +$0.15One Year Ago EPSN/ASagimet Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASagimet Biosciences Announcement DetailsQuarterQ4 2024Date3/12/2025TimeBefore Market OpensConference Call DateWednesday, March 12, 2025Conference Call Time7:30AM ETUpcoming EarningsSagimet Biosciences' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Sagimet Biosciences Earnings HeadlinesSagimet Biosciences (NASDAQ:SGMT) Trading Down 1.2% - What's Next?July 10 at 2:22 AM | americanbankingnews.comSagimet Biosciences Joins the Russell 2000® and Russell 3000® IndexesJune 29, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 13 at 1:00 AM | Porter & Company (Ad)Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 22, 2026 | globenewswire.comSagimet Biosciences Announces Board Changes and Director ElectionsJune 12, 2026 | tipranks.comSagimet Biosciences Grants New Performance-Based Executive Equity AwardsJune 3, 2026 | tipranks.comSee More Sagimet Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sagimet Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sagimet Biosciences and other key companies, straight to your email. Email Address About Sagimet BiosciencesSagimet Biosciences (NASDAQ:SGMT) (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis. In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes. The company’s research platform leverages a proprietary chemokine-targeted approach to address underlying disease mechanisms rather than solely treating symptoms. By focusing on the molecular cues that recruit pro-fibrotic cells, Sagimet aims to develop therapies with the potential for disease modification in conditions that today have limited treatment options. Headquartered in the San Francisco Bay Area, Sagimet Biosciences operates research and development facilities that support both in-house discovery and collaborative initiatives with academic and industry partners. Since its formation in 2020, the company has built a team of scientists and clinicians with expertise in fibrosis biology, protein engineering and translational medicine. This multidisciplinary organization is structured to accelerate candidates from early discovery through proof-of-concept studies. Sagimet’s leadership team is led by President and Chief Executive Officer Dr. Steven Landis, a recognized expert in fibrotic disease research and a co-founder of the company’s predecessor, Cirius Therapeutics. Under Dr. Landis’s guidance, Sagimet has established a clear clinical development plan for CM-101 and is advancing strategic collaborations to expand its pipeline. The company’s strategic vision is centered on delivering first-in-class and best-in-class therapies for patients with high-unmet-need fibrotic disorders.View Sagimet Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real Profit Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
